I[ntroduction]{.smallcaps} {#sec1-1}
==========================

Coronary heart disease (CHD) and depression seriously threaten human physical and mental health worldwide.\[[@ref1]\] Depression is considered as an independent risk factor for mortality and morbidity in patients following myocardial infarction (MI).\[[@ref2][@ref3][@ref4]\] Platelet dysfunction was demonstrated as one cardiovascular risk factor for depression led by MI while the underlying physiological mechanism that links depression and CHD remains poorly understood.\[[@ref5]\] Heightened susceptibility to platelet activation may be a mechanism by which depression is a significant risk factor for ischemic heart and cerebrovascular disease and/or mortality after myocardial infarction.\[[@ref6]\] Platelet activation is a primary physiological response to limit bleeding after acute vascular insults. Platelet activation occurs in MI or chronic heart disease.\[[@ref7]\] Depression in somatically healthy patients has been proved to associate with platelet activation.\[[@ref5][@ref7]\]

Serotonin, also known as 5-hydroxytryptamine (5-HT), acts as both a neurotransmitter and a neurohormone that potentially impact depression and CHD. Serotonin has been shown to be involved in the platelet activation in depression and MI.\[[@ref8][@ref9][@ref10][@ref11]\] The biomarker of platelet activation is not confirmed yet. After stimulation of agonists, given that platelets release high concentrations of 5-HT and the activated platelets contain less 5-HT, the concentration of 5-HT in whole blood is recommended as a parameter to evaluate the extent of platelet activation.\[[@ref5][@ref12][@ref13][@ref14][@ref15][@ref16]\] The selective serotonin reuptake inhibitors are the most commonly used antidepressant drugs that target the plasma membrane serotonin transporter (SERT). The 5-HT 2A receptor (5-HT~2A~R) as a broadly existed receptor of 5-HT is vital for depression-related diseases.\[[@ref9]\]

Ginseng fruit saponins (GFS) is a kind of steroid compounds that exists in the traditional Chinese medicine. As an active ingredient of ginseng fruit, GFS plays a crucial role in the treatment of CHD through multiple metabolic pathways including inhibition of platelet aggregation.\[[@ref17][@ref18][@ref19]\] The study of Hao *et al*.\[[@ref20]\] showed that Rb1 as an important ingredient of GFS can increase the neural 5-HT concentration and decrease immobility time in the forced swimming test (FST).

Decreased 5-HT in the brain has been linked to depression, while excessive 5-HT in the blood caused platelet aggregation which is associated with MI. The 5-HT in the periphery is able to pass the blood-brain barrier. Moreover, platelet is considered to be the mirror of the brain for the similar characteristics of biochemistry and morphology. It was reported that the ingredients of GFS, such as Re and Rg1, could cure MI or depression. According to the above evidences, we assumed GFS may play an important role in regulating the 5-HT concentration in periphery and brain of MI + depression rats. This study was to quantify the levels of 5-HT, 5-HT~2A~R, and SERT in serum, platelet, and brain homogenate to evaluate the effects of GFS on serotonin and its regulator (5-HT~2A~R, SERT) in the Sprague-Dawley (SD) rats with MI, depression, and MI + depression.

M[ethods]{.smallcaps} {#sec1-2}
=====================

Experimental animals {#sec2-1}
--------------------

A total of eighty SD rats (body weight: 250--300 g, Pharmaceutical Base, Jiangsu Province, China) were allocated to four groups: MI, depression, MI + depression, and control groups (*n* = 20 in each group). Each group included saline treatment subgroup and GFS treatment subgroup (*n* = 10 in each subgroup). Rats were administered with 2 ml saline or GFS (Jilin Ji'an Yisheng Pharmaceutical Co. Ltd.) at 2 mg/100 g once a day, through gavages for 4 weeks, then were sacrificed. All SD rats were housed at a temperature of 22 ± 2°C and a humidity of 45 ± 5%, with free access to food and water.

Establishment of depression model {#sec2-2}
---------------------------------

The modified FST in this study was used, which was similar to the method reported by Porsolt *et al*.\[[@ref21]\] Briefly, each SD rat was placed in a cylinder (40 cm in height, 20 cm in diameter) containing water at 30 cm deep, 25°C. The depth of water used in this FST was modified from 15 to 30 cm so that the adult rats could not touch the bottom to avoid immobility. After a pretest session of 15 cm depth for 15 min, the rats were dried (under a warm air current) and were exposed to the modified FST for 5 min after 24 h and repeated.

Establishment of myocardial infarction model {#sec2-3}
--------------------------------------------

The SD rats were anesthetized with ketamine (40 mg/kg) and xylazine (1 mg/kg) by intramuscular injection and then were conducted with a surgical operation.\[[@ref22]\] After anesthesia, the rats were placed at the position of the spine. After disinfecting, the thorax of the rat was opened in the fourth intercostal space. The left anterior descending artery was cauterized at the midpoint through the starting point and the cardiac apex. After cauterization, the air in the thorax was squeezed out by the forefinger, and the thorax was closed with the suture. Sixteen (80%) rats survived after MI operation.

Establishment of myocardial infarction + depression model {#sec2-4}
---------------------------------------------------------

The SD rats were firstly conducted with MI surgery as described above.\[[@ref22]\] Sixteen (80%) rats survived after MI operation. Three days later, the MI rats were conducted with the modified FST mentioned above.

Sample collection and storage {#sec2-5}
-----------------------------

The blood samples were collected from tail vein and were placed into chilled tubes containing ethylenediaminetetraacetic acid. Whole blood was aliquoted and stored at −70°C. The blood was centrifuged for 15--30 min at 200 ×*g* at room temperature to obtain platelet-rich plasma (PRP) as described above,\[[@ref23]\] then PRP was aspirated and sonicated for 10 s three times on ice. To prepare isolated platelets, PRP was centrifuged for 10 min at 2100 ×*g* at 4°C and then was disposed.\[[@ref23]\]

5-hydroxytryptamine, 5-hydroxytryptamine 2A receptor, and serotonin reuptake transporter detection {#sec2-6}
--------------------------------------------------------------------------------------------------

The levels of 5-HT, 5-HT~2A~R, and SERT were detected using enzyme-linked immunosorbent assay method.

Statistical analysis {#sec2-7}
--------------------

Statistical analyses were performed using the SPSS 17.0 (SPSS Inc., Chicago, IL, USA) and Prism 5 (GraphPad Software, Inc., San Diego, CA, USA). The values of 5-HT, 5-HT~2A~R, and SERT were presented as mean ± standard error (SE). Comparisons among three or more groups were assessed using one-way analysis of variance (ANOVA). Comparisons between two subgroups were assessed using independent samples *t*-test. A *P* \< 0.05 was considered statistically significant.

R[esults]{.smallcaps} {#sec1-3}
=====================

5-hydroxytryptamine levels in different tissues {#sec2-8}
-----------------------------------------------

After treatment with saline, the serum 5-HT levels in subgroups of MI, depression, and MI + depression groups decreased significantly compared with that in the subgroup of control group (all *P* = 0.000), and the same trend could be found for 5-HT of the platelet lysate between saline treatment subgroups of MI, depression, MI + depression and control groups (*P* = 0.000, *P* = 0.000, and *P* = 0.001, vs. control group, respectively). However, no significant differences in the 5-HT levels of brain homogenate could be found between the saline treatment subgroups of MI, depression, MI + depression and control groups (*P* = 0.100, *P* = 0.532, and *P* = 0.426, vs. control group, respectively; [Figure 1a](#F1){ref-type="fig"}).

![Concentrations of 5-HT in serum, platelet lysate, and brain homogenate after saline (a) and GFS (b) treatments in MI, depression, MI + depression, and control groups. \**P* \< 0.05, versus controls. *n* = 10 in each subgroup of control and depression groups, and *n* = 8 in each subgroup of MI and MI + depression groups. 5-HT: 5-hydroxytryptamine; MI: Myocardial infarction; GFS: Ginseng fruit saponins.](CMJ-129-2913-g001){#F1}

After treatment with GFS, the serum 5-HT levels in the subgroups of MI, depression, and MI + depression groups significantly increased compared with that in subgroup of control group (*P* = 0.016, *P* = 0.007, and *P* = 0.003, respectively). Compared with that in subgroup of control group, the 5-HT levels in platelet lysate in subgroup of MI group decreased significantly (*P* = 0.000), but slightly changed in the subgroups of depression and MI + depression groups (*P* = 0.705 and *P* = 0.417, respectively); and the same trend could be found for 5-HT of the brain homogenate between GFS treatment subgroups of MI, depression, MI + depression and control groups (*P* = 0.015, *P* = 0.227, and *P* = 0.868, vs. control group; [Figure 1b](#F1){ref-type="fig"}).

Compared to those in the saline treatment subgroups, the levels of 5-HT in serum and platelet lysate statistically significantly increased in the GFS treatment subgroups of MI, depression, MI + depression groups (all *P* \< 0.05). However, the 5-HT levels in brain homogenate significantly decreased in the GFS treatment subgroups of MI and depression groups compared with those in the saline treatment subgroups (*P* = 0.025 and 0.044, respectively), and no significant difference was observed between saline and GFS treatment subgroups of MI + depression group (*P* = 0.663; [Table 1](#T1){ref-type="table"}).

###### 

The 5-HT levels in serum, platelet lysate, and brain homogenate after saline and GFS treatments (pg/ml)

  Items              Saline treatment subgroup   GFS treatment subgroup   *F*      *P*
  ------------------ --------------------------- ------------------------ -------- -------
  Serum                                                                            
   Controls          242.94 ± 32.00              289.09 ± 74.70           3.318    0.184
   MI                55.92 ± 11.58               365.16 ± 41.28           10.348   0.000
   Depression        74.63 ± 4.97                375.50 ± 35.90           16.165   0.000
   MI + depression   62.49 ± 10.20               391.66 ± 41.55           3.128    0.000
  Platelet lysate                                                                  
   Controls          80.38 ± 5.52                306.49 ± 24.91           9.805    0.000
   MI                52.25 ± 8.57                80.30 ± 0.85             16.600   0.002
   Depression        55.18 ± 4.85                302.10 ± 7.12            0.179    0.000
   MI + depression   60.78 ± 11.16               315.99 ± 18.99           0.870    0.000
  Brain homogenate                                                                 
   Controls          400.85 ± 47.67              342.71 ± 47.47           0.130    0.060
   MI                334.05 ± 57.49              265.01 ± 27.96           2.519    0.025
   Depression        376.26 ± 56.84              306.27 ± 47.73           0.634    0.044
   MI + depression   369.39 ± 95.62              347.65 ± 70.24           0.295    0.663

The data are shown as mean ± SE. *n* = 10 in each subgroup of control and depression groups, and *n* = 8 in each subgroup of MI and MI + depression groups. 5-HT: 5-hydroxytryptamine; MI: Myocardial infarction; GFS: Ginseng fruit saponins; SE: Standard error.

5-hydroxytryptamine 2A receptor levels in different tissues {#sec2-9}
-----------------------------------------------------------

Compared with that in the saline treatment subgroup of control group, the 5-HT~2A~R levels of platelet lysate significantly increased in saline treatment subgroup of MI + depression group (*P* = 0.016) and also increased in saline treatment subgroups of MI and depression groups but without significant differences (*P* = 0.466 and *P* = 0.154, respectively). On the contrary, compared with that in the saline treatment subgroup of control group, the 5-HT~2A~R levels in brain homogenate significantly decreased in the saline treatment subgroups of MI and depression groups (*P* = 0.003 and *P* = 0.006, respectively), but no significant change could be found between the saline treatment subgroups of MI + depression and control groups (*P* = 0.164; [Figure 2a](#F2){ref-type="fig"}).

![Concentrations of 5-HT~2A~R in platelet lysate and brain homogenate after saline (a) and GFS (b) treatments in MI, depression, MI + depression, and control groups. \**P* \< 0.05, versus control group. *n* = 10 in each subgroup of control and depression groups, and *n* = 8 in each subgroup of MI and MI + depression groups. 5-HT~2A~R: 5-hydroxytryptamine 2A receptor; MI: Myocardial infarction; GFS: Ginseng fruit saponins.](CMJ-129-2913-g002){#F2}

Compared with that in the GFS treatment subgroup of control group, the 5-HT~2A~R levels of platelet lysate significantly decreased in the GFS treatment subgroups of MI, depression, and MI + depression groups (all *P* = 0.000). However, compared with that in the GFS treatment subgroup of control group, the 5-HT~2A~R levels of brain homogenate significantly decreased in the GFS treatment subgroup of MI group (*P* = 0.036), but no significant differences could be found between GFS treatment subgroups of depression, MI + depression and control groups (*P* = 0.210 and *P* = 0.984, respectively; [Figure 2b](#F2){ref-type="fig"}).

Compared to those in the saline treatment subgroups, the 5-HT~2A~R levels of platelet lysate statistically significantly decreased in the GFS treatment subgroups of MI, depression, and MI + depression groups (all *P* = 0.000). The same trend could also be found for 5-HT~2A~R levels in brain homogenate between saline and GFS treatment subgroups of MI, depression, and MI + depression groups (*P* = 0.000, 0.014, and 0.006, respectively; [Table 2](#T2){ref-type="table"}).

###### 

The 5-HT~2A~R levels in platelet lysate and brain homogenate after saline and GFS treatments (pg/ml)

  Items              Saline treatment subgroup   GFS treatment subgroup   *F*      *P*
  ------------------ --------------------------- ------------------------ -------- -------
  Platelet lysate                                                                  
   Control           67.60 ± 6.33                66.59 ± 9.92             0.874    0.838
   MI                73.08 ± 5.54                13.79 ± 3.47             0.522    0.000
   Depression        78.03 ± 16.06               17.09 ± 0.82             10.697   0.000
   MI + depression   86.15 ± 15.45               23.34 ± 0.79             10.854   0.000
  Brain homogenate                                                                 
   Control           108.52 ± 10.87              82.95 ± 14.27            0.435    0.008
   MI                90.27 ± 5.31                70.71 ± 3.14             1.542    0.000
   Depression        91.56 ± 10.23               76.40 ± 2.86             7.162    0.014
   MI + depression   100.64 ± 10.33              82.85 ± 3.88             5.071    0.006

The data are shown as mean ± SE. *n* = 10 in each subgroup of control and depression groups, and *n* = 8 in each subgroup of MI and MI + depression groups. 5-HT~2A~R: 5-hydroxytryptamine 2A receptor; MI: Myocardial infarction; GFS: Ginseng fruit saponins; SE: Standard error.

Serotonin transporter levels in different tissues {#sec2-10}
-------------------------------------------------

After treatment with saline, the serum SERT levels in a subgroup of MI + depression group significantly increased compared with that in the subgroup of control group (*P* = 0.002), but no significant differences could be found between the saline treatment subgroups of MI, depression and control groups (*P* = 0.871 and 0.092, respectively). There were no significant differences in SERT levels of platelet lysate and brain homogenate between the saline treatment subgroups of MI, depression, MI + depression and control groups (platelet lysate: *P* = 0.095, 0.758, and 0.558; brain homogenate: *P* = 0.912, 0.234, and 0.515; [Figure 3a](#F3){ref-type="fig"}).

![Concentrations of SERT in serum, platelet lysate, and brain homogenate after saline (a) and GFS (b) treatments in MI, depression, MI + depression, and control groups. \**P* \< 0.05, versus control group. *n* = 10 in each subgroup of control and depression groups, and *n* = 8 in each subgroup of MI and MI + depression groups. SERT: Serotonin transporter; MI: Myocardial infarction; GFS: Ginseng fruit saponins.](CMJ-129-2913-g003){#F3}

After treatment with GFS, the serum concentration of SERT significantly decreased in subgroup of MI group (*P* = 0.000), compared with that in the subgroup of controls, but it slightly increased in the subgroup of depression and MI + depression groups without significant difference (*P* = 0.144 and *P* = 0.857). In platelet lysate, the SERT levels significantly decreased in the subgroup of MI group (*P* = 0.000) and slightly changed in the subgroups of depression and MI + depression groups (*P* = 0.698 and 0.299), compared with that in the subgroup of control group. There were no significant differences in SERT levels of brain homogenate between the subgroups of MI, depression, MI + depression and control groups (*P* = 0.359, 0.561, and 0.235; [Figure 3b](#F3){ref-type="fig"}).

Compared to those in the saline treatment subgroups, the serum SERT levels significantly decreased in the GFS treatment subgroups of MI, depression, and MI + depression groups (*P* = 0.009, 0.038, and *P* = 0.001), while the SERT levels of platelet lysate significantly decreased in GFS treatment subgroup of MI group (*P* = 0.000), significantly increased in GFS treatment subgroup of depression group (*P* = 0.019), and slightly changed in GFS treatment subgroup of MI + depression group (*P* = 0.219). No significant changes for SERT levels in brain homogenate could be found between the saline and GFS treatment subgroups in MI, depression, and MI + depression groups (MI: *F* = 0.232, *P* = 0.421; depression: *F* = 3.835, *P* = 0.076; MI + depression: *F* = 0.047, *P* = 0.642; [Table 3](#T3){ref-type="table"}).

###### 

The SERT levels in serum, platelet lysate, and brain homogenate after saline and GFS treatments (pg/ml)

  Items                   Saline treatment subgroup   GFS treatment subgroup   *F*      *P*
  ----------------------- --------------------------- ------------------------ -------- -------
  Serum SERT                                                                            
   Control                170.56 ± 33.40              157.09 ± 10.35           6.351    0.428
   MI                     167.51 ± 30.76              108.96 ± 12.25           5.455    0.009
   Depression             202.02 ± 23.32              170.62 ± 11.06           1.850    0.038
   MI + depression        234.76 ± 29.59              158.60 ± 18.85           1.133    0.001
  Platelet lysate SERT                                                                  
   Control                154.15 ± 30.67              187.12 ± 7.91            96.909   0.046
   MI                     179.95 ± 5.73               129.09 ± 12.25           1.517    0.000
   Depression             158.24 ± 19.85              190.46 ± 10.88           1.775    0.019
   MI + depression        161.94 ± 22.19              178.62 ± 18.98           0.172    0.219
  Brain homogenate SERT                                                                 
   Control                191.69 ± 25.01              194.61 ± 19.81           0.381    0.843
   MI                     193.50 ± 23.98              205.53 ± 20.70           0.232    0.421
   Depression             171.60 ± 30.52              201.47 ± 11.95           3.835    0.076
   MI + depression        202.48 ± 22.35              208.86 ± 19.2            0.047    0.642

The data are shown as mean ± SE. *n* = 10 in each subgroup of control and depression groups, and *n* = 8 in each subgroup of MI and MI + depression groups. SERT: Serotonin transporter; GFS: Ginseng fruit saponins; MI: Myocardial infarction; SE: Standard error.

D[iscussion]{.smallcaps} {#sec1-4}
========================

The system of serotonin played a critical role in the development of CHD and depression. Major depression is proved to be associated with serotonergic neurotransmission dysfunction. A decrease of the blood 5-HT levels was considered as a marker for depression.\[[@ref24][@ref25][@ref26]\] For instance, the Cleare\'s study\[[@ref27]\] showed a decreased level of serotonin in the patients who were diagnosed with major depression. The symptoms of major depression have been identified as independent risk factors of cardiac morbidity and mortality for those patients who were diagnosed with ischemic heart disease.\[[@ref28]\] The data of the heart and soul study indicated that depression was independently associated with high concentration of serotonin in whole blood that was obtained from the patients who were diagnosed with CHD.\[[@ref29]\] The variation of 5-HT was closely connected with the upregulation or downregulation of peripheral 5-HT receptors and SERT.\[[@ref30]\] A study by Nemeroff *et al*.\[[@ref9]\] showed the decreased level of 5-HT in the hippocampus of the depression rats, while the expression of 5-HT~2A~R increased. The increased effects on activation of 5-HT~2A~R could be explained by increased amount of receptors on the platelet membrane, increased affinity of receptors, or active sensitivity in signal transmission. SERT as the transporter of 5-HT is responsible for balancing the concentration intracellular and extracellular 5-HT. In platelet, the SERT levels of plasma membrane and the uptake of 5-HT levels initially rose as the plasma 5-HT levels increased but fell below the normal limit as the plasma 5-HT level continued to rise.\[[@ref31]\] In addition, 5-HT plays a role in vasoconstriction and vasodilatation, presenting as an inhibitor of the sympathetic nervous system at different levels. First, the release of norepinephrine can be inhibited by the level of 5-HT at the sympathetic neuroeffector junction in blood vessels through the interactions with the presynaptic inhibitory 5-HT receptor.\[[@ref32]\] Second, the sympathetic outflow was centrally modified by the level of 5-HT,\[[@ref33]\] and the changes in the activity of preganglionic sympathetic nerves can be observed. Third, the sympathetic ganglionic activity, such as postganglionic sympathetic nerve activity, can be modified by the level of 5-HT.\[[@ref33]\]

Our results showed that the 5-HT level was increased after treatment with GFS due to a decreased level of 5-HT~2A~R and up- or down-regulated levels of SERT in serum. In the previous studies, the plasma membrane SERT levels and uptake of 5-HT initially rose when platelets were exposed to an increased level of 5-HT, followed by a reduce in the level of SERT (below baseline) led by a higher concentration of 5-HT.\[[@ref34]\]

Some studies suggested that the level of serotonin in brain can be evaluated by the blood 5-HT level and be used as a peripheral biomarker for depression or other mental disorders. However, the results from the clinical observations were inconsistent.\[[@ref25][@ref34][@ref35]\] Our study showed different variation of 5-HT levels in serum, platelet lysate, and brain homogenate after saline or GFS treatments, which suggested that this peripheral index was not a direct reflector of central 5-HT levels, which was consistent with the results of Li *et al*.\'s study.\[[@ref36]\]

In conclusion, this study indicated that GFS might inhibit the reuptake of 5-HT from serum to platelet according to decreased 5-HT~2A~R in platelet and SERT in serum and platelet. The change of 5-HT in serum after GFS treatment was inconsistent with that in the brain. It seemed that GFS could not pass through the blood-brain barrier to affect the central serotonergic system. Further studies are needed to confirm it in the future.
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